Valuation: Sera Prognostics, Inc.

Market Cap 78.71M 69.04M 63.74M 58.9M 112M 7.54B 114M 766M 298M 3.69B 296M 289M 12.8B P/E 2026 *
-3.07x
P/E 2027 * -3.59x
Enterprise Value 78.71M 69.04M 63.74M 58.9M 112M 7.54B 114M 766M 298M 3.69B 296M 289M 12.8B EV / Sales 2026 *
217x
EV / Sales 2027 * 29.4x
Free-Float
86.31%
Yield 2026 *
-
Yield 2027 * -
1 day+1.49%
Current month+11.54%
1 month-3.33%
3 months-8.56%
6 months-42.49%
Current year-31.19%
1 week 1.79
Extreme 1.7901
2.12
1 month 1.72
Extreme 1.725
2.24
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
15.5
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 31/05/2023
Director of Finance/CFO 39 06/06/2023
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Chairman 74 19/04/2011
Chairman 58 07/06/2023
Director/Board Member 59 31/10/2011
Date Insider Type Main position Quantity % Market Cap.
06-10Sell

General Counsel

-2,179 0.0057%
06-10Sell

Chief Technology Officer

-362 0.0009%
06-10Sell

Chief Financial Officer

-2,037 0.0053%
Change 5-day change 1-year change 3-year change Capi.($)
+1.00%0.00%-25.37%-38.30% 78.71M
-1.58%-0.02%+12.93%+15.63% 23.34B
-2.59%-13.20%+20.96% - 17.82B
-5.23%-16.05%+83.88%+50.71% 3.72B
-3.22%-2.53%+16.37%-27.37% 3.44B
-2.78%-9.42%+185.05%+193.82% 2.3B
-6.62%-7.88%+147.88%+266.01% 1.94B
-0.58%+0.92%-38.86%-46.33% 1.79B
+0.06%-1.44%-30.53% - 1.76B
-1.36%+0.66%+3.83%+10.73% 1.67B
Average -2.12%-5.04%+37.61%+53.11% 5.79B
Weighted average by Cap. -1.86%-5.50%+28.31%+35.38%

Financials

2026 *2027 *
Net sales 362K 318K 294K 271K 514K 34.71M 524K 3.53M 1.37M 16.99M 1.36M 1.33M 58.96M 2.68M 2.35M 2.17M 2M 3.79M 256M 3.87M 26.04M 10.12M 125M 10.05M 9.83M 435M
Net income -33.26M -29.17M -26.93M -24.89M -47.17M -3.18B -48.12M -324M -126M -1.56B -125M -122M -5.41B -29.98M -26.29M -24.28M -22.43M -42.52M -2.87B -43.37M -292M -113M -1.4B -113M -110M -4.88B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
08/07/26 US$2.030 +1.00% 10,582
07/07/26 US$2.010 -3.83% 7,833
06/07/26 US$2.090 +4.50% 59,989
02/07/26 US$2.000 -1.48% 25,951
01/07/26 US$2.030 +11.54% 24,333
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.010USD
Average target price
5.500USD
Spread / Average Target
+173.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock